<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335151">
  <stage>Registered</stage>
  <submitdate>11/02/2010</submitdate>
  <approvaldate>9/03/2010</approvaldate>
  <actrnumber>ACTRN12610000199011</actrnumber>
  <trial_identification>
    <studytitle>Comparative Study of the Efficacy and Safety of  two presentations of Bimatoprost 0.03% available in Brazil: Glamigan(registered trademark) and Lumigan(registered trademark).</studytitle>
    <scientifictitle>In glaucoma or ocular hypertension, have the two presentations of bimatoprost 0.03% availabe in Brazil similar safety and efficacy profile?</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>glacoma</healthcondition>
    <healthcondition>ocular hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>bimatoprost 0.03% eye drops: Lumigan(registered trademark) versus Glamigan(registered trademark), 45 days of treatment with each</interventions>
    <comparator>cross-over study: the same individual will use both bimatoprost 0.03% presentations at different time frames, and collected data will be compared. Lumigan(registered trademark) treatment cycle versus Glamigan(registered trademark) treatment cycle, 45 days each cycle, witha a 30-day washout period in between.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>diurnal curve of intraocular pressure (Goldmann Applanation Tonometry, at 08:00, 10:00, 12:00, 14:00, 16:00, 18:00)</outcome>
      <timepoint>Basal Visit (time 0 - no medication)
Visit 1 (15 days with medication A)
Visit 2 (45 days with medication A)
Visit 3 (after 30 days of washout of medication A and 15 days with medication B)
Visit 4 (45 days with medication B)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Visual Acuity (logMAR)</outcome>
      <timepoint>Basal Visit (time 0 - no medication)
Visit 1 (15 days with medication A)
Visit 2 (45 days with medication A)
Visit 3 (after 30 days of washout of medication A and 15 days with medication B)
Visit 4 (45 days with medication B)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ocular Surface Disease Index (OSDI)</outcome>
      <timepoint>Basal Visit (time 0 - no medication)
Visit 1 (15 days with medication A)
Visit 2 (45 days with medication A)
Visit 3 (after 30 days of washout of medication A and 15 days with medication B)
Visit 4 (45 days with medication B)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disk Damage Likelihood Scale - DDLS</outcome>
      <timepoint>Basal Visit (time 0 - no medication)
Visit 1 (15 days with medication A)
Visit 2 (45 days with medication A)
Visit 3 (after 30 days of washout of medication A and 15 days with medication B)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ocular Inflammation (laser flare meter)</outcome>
      <timepoint>Basal Visit (time 0 - no medication)
Visit 1 (15 days with medication A)
Visit 2 (45 days with medication A)
Visit 3 (after 30 days of washout of medication A and 15 days with medication B)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Ocular Hypertension:
- intraocular pressure higher than 21mmHg with no medication
-normal visual field test
-normal optic nerve appearance

Glaucoma:
-intraocular pressure higher than 21mmHg with no medication
-glaucomatous visual filed test
-glacuomatous optic nerve appearance</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- visual acuity worse than 20/40 (Snellen scale)
- intraocular pressure higher than 36mmHg with medication
- diabetes
-intraocular laser or surgery on the last 6 months
-ocular trauma on the last 6 months</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>allocation is not concealed</concealment>
    <sequence>dice-rolling</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/05/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>54</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Ophthalmology Department of the State University of Campinas</primarysponsorname>
    <primarysponsoraddress>Rua Vital Brasil, 251
Distrito de Barao Geraldo
Campinas
Sao Paulo</primarysponsoraddress>
    <primarysponsorcountry>Brazil</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Germed Pharma ltda</fundingname>
      <fundingaddress>Rua Dr Emilio Rimas, 188
Cambui
Campinas
Sao Paulo</fundingaddress>
      <fundingcountry>Brazil</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of the study is to compare the safety and efficacy of the two avalable presentations of bimatoprost 0.03% in Brazil. We intent to compare the reduction of the intraoclular pressure with the two deifferent presentations and observe the incidence of side effects.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics in Resear Board of the State University of Campinas</ethicname>
      <ethicaddress>Rua Tessalia Vieira de Camargo, 126 
Distrito de Barao Geraldo
Campinas
Sao Paulo</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>1/03/2010</ethicsubmitdate>
      <ethiccountry>Brazil</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Alvaro Lupinacci</name>
      <address>Rua Hermantino Coelho, 501 apto 144W
CEP 13027-500
Campinas - Sao Paulo</address>
      <phone>55-19-33676432</phone>
      <fax />
      <email>alvaro.lupinacci@gmail.com</email>
      <country>Brazil</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Alvaro Lupinacci</name>
      <address>Rua Hermantino Coelho, 501 apto 144W
CEP 13027-500
Campinas - Sao Paulo</address>
      <phone>55-19-33676432</phone>
      <fax />
      <email>alvaro.lupinacci@gmail.com</email>
      <country>Brazil</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>